NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC
The Screen · Healthcare · Medical Care Facilities
National Medical Care
4009.SR · TADAWUL · SAR · Market cap $3.0B
Middle East Healthcare Company, a healthcare provider, owns and operates a network of hospitals under the Saudi German Hospital name in the Kingdom of Saudi Arabia and internationally.
FAIL · Does not pass the screen
32.20 SAR
At the last full screen 2025-12-31
Screened 2025-12-31 · the tape above runs as of 23:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 32.20 against the desk's fair-value range, base estimate 54.34, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price32.20 SAR
Fair value54.34
Ethical score70.0/100
RatingAVOID
Our investment reviews on this name
2026-09-18Read Markdown32.20+0.0% to today
2026-07-02Read Distribution32.20+0.0% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
National Medical Care holds its Markdown at $32.20. The statistical read favours the buyers, held for 52 days.
As held on the ledger · 2025-12-31
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 52 days
Price at the screen
$32.20
Valuation
7.89 trailing · 8.61 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.05
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
46.53%
Below 33%
Interest-bearing debt is 46.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
37.37%
Below 49%
Money owed to the company is 37.4% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 69% discount to our $54.34 fair value, 4.30% revenue growth.
Fair value range in SAR, drawn from the 2025-12-31 screen. The gold marker is the market price at the same screen. A 68.8% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus Hold. The average target sits +110% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2025-12-31 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 8.6x forward earnings, the price already runs ahead of the business. Our fair value sits at $54.34, below where it trades today.
The risks · The things to watch: its business and earnings are exposed to Saudi Arabia and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
4009.SR trades on TADAWUL (the company is based in Saudi Arabia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-18Markdown · changed$32.20+0.0%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (4 analysts) rates it none, with a mean price target of $66.
2026-08-19Distribution$32.20+0.0%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (4 analysts) rates it none, with a mean price target of $66.
2026-07-19Distribution$32.20+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (4 analysts) rates it none, with a mean price target of $66.
2026-07-18Distribution$32.20+0.0%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (4 analysts) rates it none, with a mean price target of $66.
2026-07-15Distribution$32.20+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-03Distribution$32.20+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$32.20Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$34.42
-6.7%
·
$933
-6.7%
2 months
$36.60
-12.3%
·
$877
-12.3%
3 months
$32.20
-0.3%
·
$997
-0.3%
6 months
$37.00
-13.2%
·
$868
-13.2%
1 year
$57.50
-44.2%
$0.50
$567
-43.3%
2 years
$82.78
-61.2%
$0.50
$394
-60.6%
3 years
$67.12
-52.2%
$0.50
$486
-51.4%
5 years
$38.07
-15.7%
$0.50
$856
-14.4%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever 4009.SR does next, these words stay.
National Medical Care · 4009.SR · Markdown · $32.20
Recorded 2025-12-31 · before the outcome · scored mechanically